PD-1 and PD-1 ligands: from discovery to clinical application
The DOI matches its Crossref record; 133 of the 138 references it cites were found in a registry or an index.
Abstract
Programmed cell death-1 (PD-1, Pdcd1), an immunoreceptor belonging to the CD28/CTLA-4 family negatively regulates antigen receptor signaling by recruiting protein tyrosine phosphatase, SHP-2 upon interacting with either of two ligands, PD-L1 or PD-L2. Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege. In this review, we would like to summarize the history of PD-1 research since its discovery and recent findings that suggest promising future for the clinical application of PD-1 agonists and antagonists to various human diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“PD-1 interacts with an SHP2 tyrosine phosphatase domain, leading to dephosphorylation of signaling molecules downstream of the TCR and inhibiting TCR-mediated activation of IL2 production and T-cell proliferation (13).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [13]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Nguyen, L. T., Radhakrishnan, S., Ćirić, B., Tamada, K., Shin, T., Pardoll, D. M., Chen, L., Rodriguez, M., & Pease, L. R. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20021466 · Cited by 105 · cited 1×
“However, one group reported that cross-linking of PD-L2 induces stimulatory signal in dendritic cells (DCs), resulting in the augmented antigen presentation ( 26 , 27).”
BackgroundRetractedRadhakrishnan, S., Nguyen, L. T., Ćirić, B., Ure, D., Zhou, B., Tamada, K., Dong, H., Tseng, S.-Y., Shin, T., Pardoll, D. M., et al. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.4.1830 · Cited by 73
RetractedFreeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Tolerance, Danger, and the Extended Family
Matzinger, P. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.005015 · Cited by 4,820
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2006) · Nature · doi:10.1038/nature04444 · Cited by 3,986
Ishida, Y., Agata, Y., Shibahara, K., & Honjo, T. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05481.x · Cited by 3,256
Iwai, Y., Ishida, M., Tanaka, Y., Okazaki, T., Honjo, T., & Minato, N. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192461099 · Cited by 3,203
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
Latchman, Y., Wood, C. R., Chernova, T., Chaudhary, D., Borde, M., Chernova, I., Iwai, Y., Long, A. J., Brown, J. A., Nunes, R., et al. (2001) · Nature Immunology · doi:10.1038/85330 · Cited by 2,955
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Self-citation
Cited by
Items 901–1,000 of 1,001
A novel humanized anti-PD-1 monoclonal antibody potentiates therapy in oral squamous cell carcinoma
Cai, Y., Wang, F., Liu, Q., Li, Z., Li, D., & Sun, Z. (2018) · Investigational New Drugs · doi:10.1007/s10637-018-0678-6 · Cited by 7
Dillman, R. O., Nistor, G. I., & Poole, A. J. (2019) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2019.1680239 · Cited by 6
“Programmed death molecule-1 (PD-1) is induced on lymphocytes by IFN-γ and is associated with down-regulation of a Th1 response.(32,33) Galectin-3 is a member of the beta galactoside-bindng protein family and is involved in macrophage activation, chemo-attraction, angiogenesis, inflammation, cellcell adhesion, cancer m…”
BackgroundMunhoz, L. G. C., Spina, F. G., Machado, D. M., Gouvêa, A. D. F. T. B., Succi, R. C. D. M., Diaz, R. S., & de Moraes‐Pinto, M. I. (2019) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000002446 · Cited by 7
“PD-1 is expressed on CD4 T and CD8 T cells when they are activated,(5) interacting with different cell populations.(6) Evaluation of children with HIV infection with respect to cytokine profile is scarce.”
BackgroundPagkopoulou, E., Simopoulou, T., Maragkouli, E., Perifanou-Sotiri, S., Kotsakis, A. P., & Bogdanos, D. P. (2020) · Mediterranean Journal of Rheumatology · doi:10.31138/mjr.31.3.355 · Cited by 7
Tavakolpour, V., Kharkeshi, M. S., Soleimanpour‐Lichaei, H. R., Gardaneh, M., & Kouhkan, F. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102211 · Cited by 7
Dual-function polyester nanoparticles for amplified anti-inflammatory effects
Heyns, I. M., Wahab, A. T., Ganugula, R., Sheikh‐Hamad, D., Kumar, M. N. V. R., & Arora, M. (2025) · Science Advances · doi:10.1126/sciadv.adw1358 · Cited by 8
Uzhachenko, R. V., Ochoa, S. G., Kanagasabai, T., Rajakaruna, H., Thounaojam, M. C., de Aquino, M. T. P., Rana, T., Costa, L. A., Terekhov, A. S., Hofmeister, W. H., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1593913 · Cited by 7
McNamara, M. A., Zhang, T., Harrison, M. R., & George, D. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00079-7 · Cited by 7
Boch, C., Reschke, M., Igney, F. H., Maier, P., Müller, P., Danklmaier, S., Das, K., Hofer, T., Wollmann, G., & Rist, W. (2022) · Biomedicines · doi:10.3390/biomedicines10092146 · Cited by 6
“, on CD8+ T cells, where it induces a state of functional unresponsiveness apoptosis, thus causing immune evasion of the tumor [4,5].”
BackgroundChemical immunology: Recent advances in tool development and applications
Shi, Y., Bashian, E. E., Hou, Y., & Wu, P. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.02.006 · Cited by 7
Extracellular RNA in oncogenesis, metastasis and drug resistance
Nelson, H., Qu, S., Franklin, J. L., Liu, Q., Pua, H. H., Vickers, K. C., Weaver, A. M., Coffey, R. J., & Patton, J. G. (2024) · RNA Biology · doi:10.1080/15476286.2024.2385607 · Cited by 5
Kristensen, L. G., Gupta, S., Chen, Y., Petzold, C. J., & Ralston, C. Y. (2024) · Antibodies · doi:10.3390/antib13030077 · Cited by 6
Lin, Z., Liu, Q., Wei, Q., Lin, L., Chen, X., & Xue, D. (2020) · Annals of Translational Medicine · doi:10.21037/atm-20-3928 · Cited by 6
“Anti-PD-1/PD-L1 immune checkpoint inhibitors can block PD-1 from binding with its ligands and restore the vitality of effector T cells, thus reducing the chance of immune escape (8).”
BackgroundIgG4 ‐related disease is characterised by the overexpression of immunomodulatory proteins
Arora, K. S., Kulkarni, A. S., Pankaj, A., Desai, N., & Deshpande, V. (2022) · Histopathology · doi:10.1111/his.14564 · Cited by 6
Soma, K., Nishida, T., Osugi, N., Morimura, O., Adachi, S., Fujii, Y., Sugimoto, A., Mukai, K., Nakamatsu, D., Matsumoto, K., et al. (2021) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-021-01542-z · Cited by 6
“Immune checkpoint inhibitors (ICIs) exert their antitumor effects by blocking the cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death 1 (PD-1) pathways, thereby increasing the proliferation, activation, and cytotoxicity of cancer antigen-specific T cells [1].”
A rare case of eosinophilic gastritis induced by nivolumab therapy for metastatic melanoma
Tsuji, A., Hiramatsu, K., Namikawa, S., Yamamoto, A., Midori, Y., Murata, Y., Tanaka, T., Nosaka, T., Naito, T., Takahashi, K., et al. (2022) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-022-01680-y · Cited by 8
Ding, Q., Liu, Y., Ju, H., Song, H., Xiao, Y., Liu, X., Ren, G., & Wei, D. (2020) · Medicina oral, patología oral y cirugía bucal · doi:10.4317/medoral.25919 · Cited by 6
“In recent years, immunotherapy has made breakthroughs and brought new hope to cancer patients with poor prognosis (4-7).”
BackgroundRole of PD ‐1 in Skin Cancer: Molecular Mechanism, Clinical Applications, and Resistance
Sharma, N., Mazumder, R., Rai, P., & Debnath, A. (2024) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14613 · Cited by 7
“Moreover, PD-1 exerts an impact on allergic reactions and the preservation of immunological privilege, showcasing its extensive involvement in various immunological domains (Okazaki and Honjo 2007).”
Biomarkers and novel agents in esophago-gastric cancer: are we making progress?
Dahle-Smith, Å., & Petty, R. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1071669 · Cited by 6
“Tumor cells can express the PD-1 ligand, PD-L1, which when bound to PD-1 results in inhibition of activation of the T cell (FIGURE 2) [112].”
BackgroundRelationship between programmed cell death‐1 polymorphisms and clearance of hepatitis B virus
Ülger, Y., Bayram, S., Sandıkçı, M., Akgöllü, E., & Bekar, A. (2015) · International Journal of Immunogenetics · doi:10.1111/iji.12187 · Cited by 6
“…polymorphisms because recent evidences indicated that PD-1 can play a role of mediator in a wide spectrum of immune response processes, such as infectious immunity, autoimmunity and immunological privilege (Nishimura & Honjo, 2001; Okazaki & Honjo, 2007; Sharpe et al., 2007; Dinesh et al., 2010).”
BackgroundCheckpoint inhibitors in the treatment of cutaneous malignant melanoma.
Lutzky, J. (2014) · PubMed · doi:10.3978/j.issn.2304-3865.2014.05.13 · Cited by 9
“PD-L1 is widely expressed in hematopoietic and nonhematopoietic tissues as well as in tumor cells (26-28).”
BackgroundPembrolizumab in the Treatment of Advanced Urothelial Cancer
Lundgren, K. T., Farina, M. S., & Joaquim Bellmunt, B. (2017) · Future Oncology · doi:10.2217/fon-2017-0284 · Cited by 7
Li, G., Yang, L., Li, D., Zhang, J., Du, L., Xia, L., Liu, Y., & Hu, W. (2020) · Molecular Medicine Reports · doi:10.3892/mmr.2020.10977 · Cited by 7
Zhang, Z., Cheng, S., Qi, C., Zhang, X., Peng, Z., & Shen, L. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-21-83 · Cited by 5
“Previous studies have shed light on the important roles of PD-1/ PD-L1 signaling during tumorigenesis (5).”
BackgroundImmunotherapeutic and their immunological aspects: Current treatment strategies and agents
Jain, M., Mishra, A., Singh, M. K., Shyam, H., Kumar, S., Shankar, P., & Singh, S. (2022) · National Journal of Maxillofacial Surgery · doi:10.4103/njms.njms_62_22 · Cited by 7
Furuya, T., Ishihara, S., Ogi, H., Masuda, K., Shibata, S., Nakazono, C., Okada, S., Shimomura, M., Tando, S., Yaoi, T., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03431-5 · Cited by 10
“PD-1 expression on CD8SP T cells was not significantly associated with PD-L1 expression in thymoma epithelium, Masaoka stage, or presence of autoimmune disease (Fig.”
BackgroundInfluentialSchillingmann, D. A., Riese, S. B., Vijayan, V., Tischer‐Zimmermann, S., Schmetzer, H. M., Maecker‐Kolhoff, B., Blasczyk, R., Immenschuh, S., & Eiz‐Vesper, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030482 · Cited by 6
“Binding to its ligands PD-L1 and PD-L2 leads to the inhibition of T-cell activation [39] and thus plays an important role in the regulation of T-cell responses [40,41].”
BackgroundPashov, A. D., Puente, C. V. H., Ibrahim, S. M., Monzavi‐Karbassi, B., Makhoul, I., & Kieber‐Emmons, T. (2018) · Monoclonal Antibodies in Immunodiagnosis and Immunotherapy · doi:10.1089/mab.2018.0014 · Cited by 6
“(94,95) 98) It is important to realize that therapeutic application of checkpoint inhibitors necessitates that there was a primed immune response.”
Furukawa, F. (2018) · Trends in Immunotherapy · doi:10.24294/ti.v2.i1.1065 · Cited by 6
Population dynamics and gene regulation of T cells in response to chronic antigen stimulation
Hsiung, S., & Egawa, T. (2022) · International Immunology · doi:10.1093/intimm/dxac050 · Cited by 7
Tong, J., Gao, P., Xiao, X., Liu, Y., & Xu, H. (2024) · ChemistrySelect · doi:10.1002/slct.202302813 · Cited by 5
Klimek, J., Kruc, O., Ceklarz, J., Kamińska, B., Musielak, B., van der Straat, R., Dömling, A. S. S., Holak, T. A., Muszak, D., Kalinowska‐Tłuścik, J., et al. (2024) · Molecules · doi:10.3390/molecules29112646 · Cited by 6
Gut IgA functionally interacts with systemic IgG to enhance antipneumococcal vaccine responses
Gutzeit, C., Grasset, E. K., Matthews, D. B., Maglione, P. J., Britton, G. J., Miller, H., Magri, G., Tomalin, L. E., Stapylton, M., Canales-Herrerías, P., et al. (2025) · Science Advances · doi:10.1126/sciadv.ado9455 · Cited by 8
Detection of high PD-L1 expression in oral cancers by a novel monoclonal antibody L1Mab-4
Yamada, S., Itai, S., Kaneko, M. K., & Kato, Y. (2018) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2018.01.009 · Cited by 5
Thanarajasingam, U., & Abdel‐Wahab, N. (2020) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2020.04.003 · Cited by 7
DNA Mismatch Repair System Imbalances in Breast Adenocarcinoma
Metaxas, G. I., Tsiambas, E., Marinopoulos, S. S., Αδαμοπούλου, Μ., Spyropoulou, D., Falidas, E., DAVRIS, D., Manaios, L., Fotiades, P. P., Mastronikoli, S., et al. (2023) · Cancer Diagnosis & Prognosis · doi:10.21873/cdp.10197 · Cited by 6
lncRNA MIAT promotes luminal B breast cancer cell proliferation, migration, and invasion in vitro
Mi, J., Zhang, H., Jiang, X., Yi, Y., Cao, W., Song, C., & Yuan, C. (2023) · Journal of Applied Genetics · doi:10.1007/s13353-023-00807-2 · Cited by 7
“…the PD-1/ PDL1 pathway in the tumor microenvironment of several aggressive cancers (metastatic melanoma, non-small cell lung cancer, kidney cancer, and bladder cancer) are able to release immune cell effector functions (Topalian et al. 2012; Okazaki and Honjo 2007; Sharma and Allison 2015).”
Fujiwara, M., Shimizu, M., Okano, T., Maejima, Y., & Shimomura, K. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1264056 · Cited by 5
Cho, T., Wierk, A., Gertsenstein, M., Rodgers, C. E., Uetrecht, J., & Henderson, J. T. (2024) · Toxicological Sciences · doi:10.1093/toxsci/kfae003 · Cited by 5
“Ultimately, PD-1 has been studied extensively in mice and humans, and there are inter-and intraspecies differences (Okazaki and Honjo, 2007).”
BackgroundYadigaroglu, K., Scharf, S., Gretser, S., Schäfer, H., Deli, A. S. S., Loth, A. G., Yegoryan, H., Schmitz, R., Donnadieu, E., Hansmann, M., et al. (2024) · Haematologica · doi:10.3324/haematol.2023.284512 · Cited by 7
Peiser, M., Hitzler, M., & Luch, A. (2013) · Proceedings of the Fourth International Symposium on Polarization Phenomena in Nuclear Reactions · doi:10.1007/978-3-0348-0726-5_9 · Cited by 6
Immunological in vivo effects of B7-H1 deficiency
Bazhin, A. V., von Ahn, K., Maier, C., Soltek, S., Serba, S., Diehl, L., Werner, J., & Karakhanova, S. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.08.013 · Cited by 6
Rowdo, F. P. M., Lacreu, M. L., & Mordoh, J. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00103 · Cited by 5
“Physiological functions of the PD pathway are altered in cancer (Okazaki and Honjo, 2007).”
BackgroundPD-L1 and Other Immunological Diagnosis Tools
Giraldo, N. A., & Taube, J. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_23 · Cited by 7
Rationnel biologique de l’immunothérapie des cancers
Benzaquen, J., Marquette, C., Glaichenhaus, N., Leroy, S., Hofman, P. M., & Ilié, M. (2018) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2017.11.008 · Cited by 7
Ghapanchi, J., Ghaderi, H., Haghshenas, M. R., Jamshidi, S., Rezazadeh, F., Azad, A., Farzin, M., Derafshi, R., & Kalantari, A. H. (2019) · Asian Pacific Journal of Cancer Prevention · doi:10.31557/apjcp.2019.20.2.421 · Cited by 5
“In particular, most studies have focused on proteins that regulate the immune system, as well as other factors that impact autoimmunity (Okazaki and Honjo, 2007; Neshat et al., 2013, Ghapanchi et al., 2014).”
BackgroundKazufumi, S., Koshikawa, S., Shinya, K., Watanabe, H., Izumi, M., Yoshimura, K., & Sueki, H. (2021) · The Journal of Dermatology · doi:10.1111/1346-8138.15977 · Cited by 5
Zhang, Y., Zhang, L., Sun, H., Liu, Y., Xu, J., Huang, H., Fu, J., Zhang, D., Tian, T., Zhao, Y., et al. (2021) · Molecular Medicine · doi:10.1186/s10020-021-00373-5 · Cited by 5
Atezolizumab-induced bilateral anterior uveitis: A case report
Mito, T., Takeda, S., Motono, N., & Sasaki, H. (2021) · American Journal of Ophthalmology Case Reports · doi:10.1016/j.ajoc.2021.101205 · Cited by 5
Kimura, Y. (2021) · Nutrition and Cancer · doi:10.1080/01635581.2021.1985532 · Cited by 5
Meng, Y., Chu, C., Niu, X., Cheng, L., Wu, D., Liu, L., Zhang, S., Li, T., Hou, Y., Liu, Y., et al. (2022) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2022.128647 · Cited by 5
Walker, K., Waters, L. C., Kelly, G. P., Muskett, F. W., & Carr, M. D. (2022) · Biomolecular NMR Assignments · doi:10.1007/s12104-022-10092-5 · Cited by 4
“These effects are achieved by modulating the threshold of T-cell activation via intracellular signalling through PD-1 expressed on T-cells, which is inhibitory to T-cell Receptor signalling (Okazaki and Honjo 2007).”
BackgroundAn integrated bioinformatics analysis of the S100 in head and neck squamous cell carcinoma
Bai, G., Yue, S., You, Y., Zhao, J. X., Tian, Z., Wang, Y., Zhang, Z., & Yang, C. (2023) · Translational Cancer Research · doi:10.21037/tcr-22-1353 · Cited by 9
“The other S100 proteins also showed clinical and pathological significance in HNSCC. Overexpression of S100A1 enhances the cancer cell proliferation, migration and lymph node metastasis in cervical cancer (28), breast cancer (29), and hepatocellular carcinoma (31).”
Yamamoto, M., Tanaka, Y., Takeda, R., Nakamoto, A., Nakamoto, M., Yagita∥, H., & Sakai, T. (2023) · Journal of Clinical Biochemistry and Nutrition · doi:10.3164/jcbn.23-76 · Cited by 5
Tumor Microenvironment Regulates Immune Checkpoints: Emerging Need of Combinatorial Therapies
Kalia, M., Bhavya, K., & Pal, D. (2024) · Current Tissue Microenvironment Reports · doi:10.1007/s43152-023-00052-z · Cited by 6
“PD-1 expression necessitates the involvement of various immune cell types, including T cells, B cells, dendritic cells, monocytes, tumor-infiltrating lymphocytes (TILs), and antigen-presenting cells (APCs) [45].”
del Cañizo, C. G., Jiménez, M. R.-I., Vallejo, E. P., Ojeda, J. M. D., Kehrman, F. D. L. R., Rodríguez-Antolín, A., & Guerrero‐Ramos, F. (2020) · Actas Urológicas Españolas · doi:10.1016/j.acuro.2020.06.011 · Cited by 4
Wu, J., Chang, K., Ni, Y., Hsu, H., & Chang, M. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa545 · Cited by 5
PD-1 Expression and its Correlation With Prognosis in Clear Cell Renal Cell Carcinoma
Kim, M. H., KO, G. H., LEE, J. H., Lee, J. S., Kim, D. C., Yang, J. W., An, H. J., Na, J. M., & Song, D. H. (2021) · In Vivo · doi:10.21873/invivo.12409 · Cited by 5
Endocrine dysfunctions during treatment of immune-checkpoint inhibitors
Inaba, H., Ariyasu, H., Okuhira, H., Yamamoto, Y., Akamatsu, H., Katsuda, M., Jinnin, M., Hara, I., & Akamizu, T. (2020) · Trends in Immunotherapy · doi:10.24294/ti.v4.i1.606 · Cited by 5
Clinical characteristics and PD-L1 expression in primary lung squamous cell carcinoma: A case series
Fernández‐Trujillo, L., García-Robledo, J. E., Zúñiga-Restrepo, V., & Sua, L. F. (2020) · Respiratory Medicine Case Reports · doi:10.1016/j.rmcr.2020.101114 · Cited by 6
Psychedelics and ketamine are a symptom of psychiatry’s woes, not a cure
Miller, A. H., & Raison, C. L. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02132-w · Cited by 5
“…psychedelics or ketamine, checkpoint inhibitors and targeted therapies including the tyrosine kinase inhibitors were designed based on mechanistic understandings of host tumor responses and tumor biology and were re fi ned and further developed based on their outcomes in clinical trials [2, 4].”
BackgroundMethodTumor-associated macrophages: orchestrators of the tumor microenvironment
Echols, J. B., Meehan, A. W., Marotto, K., Ordonez, V., & Hildreth, B. E. (2026) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00834.2025 · Cited by 4
Richtmann, S., Marwitz, S., Muley, T., Koistinen, H. K., Christopoulos, P., Thomas, M., Kazdal, D. N., Allgäuer, M., Winter, H., Goldmann, T., et al. (2024) · Translational research · doi:10.1016/j.trsl.2024.02.007 · Cited by 4
Nanobodies as innovative immune checkpoint modulators: advancing cancer immunotherapy
Hosseininejad-Chafi, M., Eftekhari, Z., Oghalaie, A., Behdani, M., Sotoudeh, N., & Kazemi‐Lomedasht, F. (2024) · Medical Oncology · doi:10.1007/s12032-024-02588-y · Cited by 4
“Although initially identified in cells undergoing apoptosis, its primary function is now known to be unrelated to cell death [64].”
InfluentialJapanese Science Policies and Their Impacts on Scientific Research
Muto, A. (2025) · Publications · doi:10.3390/publications13020027 · Cited by 5
Bianconi, E., Riccio, A., Ruta, L., Bigiotti, C., Carotti, A., Moretti, S., Cerra, B., Gioiello, A., Ferlin, S., Puxeddu, E., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065535 · Cited by 4
“PD-1 is mainly expressed on activated mature T cells and on double-negative (CD4−CD8−) T cells, activated natural killer T cells, B cells, monocytes, and immature Langerhans cells to a lower extent [3].”
BackgroundHlaing, S. T. M., Damayanti, P., Aung, K. Z., Tsukino, H., Hinoura, T., & Kuroda, Y. (2023) · Cureus · doi:10.7759/cureus.48120 · Cited by 4
“3, encodes a type 1 trans-membranous glycoprotein protein of 50-55kDa [12].”
BackgroundReview of T Helper 2-Type Inflammatory Diseases Following Immune Checkpoint Inhibitor Treatment
Mima, Y., Ohtsuka, T., Ebato, I., Nakata, Y., Tsujita, A., Nakazato, Y., & Norimatsu, Y. (2024) · Biomedicines · doi:10.3390/biomedicines12081886 · Cited by 7
“PD-1, a member of the immunoglobulin superfamily, functions as an inhibitory receptor found in activated T cells and B cells that helps to maintain peripheral tolerance [31].”
BackgroundZhao, B., Xuan, R., Yang, G., Hu, T., Chen, Y., Cai, L., Hu, B., Ling, G., & Xia, Z. (2025) · Discover Oncology · doi:10.1007/s12672-025-01889-6 · Cited by 4
“These markers are known to be involved in immune evasion mechanisms utilized by tumors [71, 72].”
PLATE, J. M. D., & Fidler, M. J. (2010) · Immunotherapy · doi:10.2217/imt.10.62 · Cited by 4
Adverse Effects of Modern Treatment of Malignant Melanoma and their Treatment/ Management
Kopecký, O., Kubeček, O., Trojanová, P., Kubala, E., & Kopecký, J. (2014) · Klinicka onkologie · doi:10.14735/amko2014393 · Cited by 4
Watanabe, M., Kanda, J., Hishizawa, M., Nishikori, M., Kondo, T., Yamashita, K., & Takaori‐Kondo, A. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04084-5 · Cited by 4
Starzyńska, A., Sejda, A., Adamski, Ł. J., Adamska, P., Pęksa, R., Sakowicz‐Burkiewicz, M., Wychowański, P., & Jereczek‐Fossa, B. A. (2020) · Advances in Dermatology and Allergology · doi:10.5114/ada.2020.98522 · Cited by 5
Zhang, Y. X., Mou, G.-Z., Li, T., Xu, W., Zhang, T., Xue, H. Y., Zuo, W., Li, Y., Luo, Y., & Jin, C. (2021) · Technology in Cancer Research & Treatment · doi:10.1177/15330338211004942 · Cited by 7
“PD-1 bound to PD-L1, PD-L2, or the corresponding antibodies can play an immunosuppressive role around the tumor, resulting in the downregulation of T cells activity and promoting tumor cells evasion of immune surveillance.(2,3) Unlike traditional treatments that directly kill large areas of tumor tissue, anti-PD-1 imm…”
BackgroundHahn, A. W., Shah, A. Y., & Campbell, M. T. (2021) · Kidney Cancer · doi:10.3233/kca-210123 · Cited by 6
“PD-1 is another inhibitory checkpoint expressed on T cells that diminishes T-cell activation, when engaged by PD-L1 or PD-L2, by inhibiting IL-2 production and T-cell proliferation [14].”
Horozoğlu, C., Sönmez, D., Demirkol, Ş., Hakan, M. T., Kaleler, İ., Hepokur, C., Verim, A., & Yaylım, İ. (2021) · Pathology - Research and Practice · doi:10.1016/j.prp.2021.153665 · Cited by 4
Li, X. N., Zeng, Q., Xu, F., Jiang, Y.-Y., & Jiang, Z. (2022) · Molecular Diversity · doi:10.1007/s11030-022-10509-2 · Cited by 4
Su, T., Wang, S., Huang, S., Cai, H., McKinley, E. T., Beeghly-Fadiel, A. C., Zheng, W., Shu, X., & Cai, Q. (2022) · Cancer Biomarkers · doi:10.3233/cbm-220071 · Cited by 4
“The PD-1/PD-L1 pathway plays a subtle role in maintaining peripheral T-lymphocyte tolerance and seems to be one of the major immune escape mechanisms, inversely correlated with survival in breast cancer [42,43].”
Dursun, F. Ş. K., & Alabalık, U. (2022) · Polish Journal of Pathology · doi:10.5114/pjp.2022.119752 · Cited by 4
Comparative analysis of calcified soft tissues revealed shared deregulated pathways
Ibragimova, A. G., Stanishevskiy, Y. M., Plakkhin, A. M., Zubko, A. V., Darvish, N. A., Koasari, A. K., & Shindyapina, A. V. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1131548 · Cited by 6
Immunotherapy as a Turning Point in the Treatment of Melanoma Brain Metastases
Fernandes, G. N. C. (2023) · Discoveries · doi:10.15190/d.2023.8 · Cited by 4
Ching, K. W. C., Nazri, M. N. M., Rachman, A. R. A., Mustafa, K. M. F., & Mokhtar, N. F. (2022) · Journal of Preventive Diagnostic and Treatment Strategies in Medicine · doi:10.4103/jpdtsm.jpdtsm_17_22 · Cited by 4
Yu, L., Huang, A., Wang, W., Du, R., Shen, L., & Hou, X. (2011) · Journal of Huazhong University of Science and Technology [Medical Sciences] · doi:10.1007/s11596-011-0476-2 · Cited by 4
“PD-L1 is expressed on leucocytes, non-hematopoietic cells and in non-lymphoid tissues, and PD-L2 expression is restricted to DC and monocytes [31, 32 ] . In the liver, PD-L1 can be”
BackgroundSolimando, D. A., & Waddell, J. A. (2015) · Hospital Pharmacy · doi:10.1310/hpj5005-356 · Cited by 4
Shrestha, R., Petley, E. V., Farrand, K. J., Jamieson, S. A., Jiao, W., Teesdale‐Spittle, P. H., Mace, P. D., Hermans, I. F., & Rendle, P. M. (2020) · ChemMedChem · doi:10.1002/cmdc.202000221 · Cited by 4
Costimulation of Th17 cells: adding fuel or putting out the fire in the inflamed gut?
Zhang, Z., Rosenbaum, J. T., Zhong, W., Lim, C., & Hinrichs, D. J. (2010) · Seminars in Immunopathology · doi:10.1007/s00281-009-0190-3 · Cited by 4
“The regulatory function of PD-1 is also substantiated by the reports that singlenucleotide polymorphisms of PD-1 have been linked to various human autoimmune diseases including systemic lupus erythematosus, rheumatoid arthritis, insulin-dependent diabetes, multiple sclerosis, ankylosing spondylitis, and allergy [110,…”
BackgroundKibirige, C. N., Menendez, F. A., Zhang, H., Nilles, T. L., Langan, S. J., & Margolick, J. B. (2014) · Medical Hypotheses · doi:10.1016/j.mehy.2014.04.005 · Cited by 4
“PD-1 and PD-L1 blockers have been shown to be effective at reviving CD8 effector function during HIV infection [54].”
Liu, Q., Lv, Y., Zhao, M., Jin, Y., & Lu, J.-Y. (2015) · Europe PMC (PubMed Central) · Cited by 4
Bulutay, P., Firat, P., Zeren, E. H., Erus, S., Tanju, S., & Dilege, Ş. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-2004-61 · Cited by 4
Role of Cytokines in Liver Fibrosis
Anapalı, M., & Balkan, E. (2021) · Kafkas Journal of Medical Sciences · doi:10.5505/kjms.2021.75537 · Cited by 6
First PD-1 inhibitor breezes across finish line
Sheridan, C. (2014) · Nature Biotechnology · doi:10.1038/nbt0914-847 · Cited by 4
Immune checkpoint inhibitors and irAEs
Furukawa, F. (2018) · Trends in Immunotherapy · doi:10.24294/ti.v2.i2.930 · Cited by 4
“Because of the wide range of ligand distribution in the body, its biological significance pervades almost every aspect of immune responses including autoimmunity, tumor immunity, infectious immunity, transplantation immunity, allergy and immunological privilege([2]).”
BackgroundAdvances in T-cell co-receptor biology and cancer immunotherapy
Rudd, C. E. (2019) · Seminars in Immunology · doi:10.1016/j.smim.2019.101281 · Cited by 4
Ahmadvand, N., Carraro, G., Jones, M. R., Shalashova, I., Wilhelm, J., Baal, N., Kosravi, F., Chen, C., Zhang, J., Ruppert, C., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.03.09.483616 · Cited by 4
“Pd-l1 is an immune inhibitory molecule that controls the inflammatory response to injury [15][16][17][18][19].”
BackgroundThe role of programmed cell death 1 in autoimmune diseases: mechanisms and therapeutic implications
Liu, Z., Hu, Z., Lao, H., Chen, L., Wen, Y., Liang, Y., Zhang, C., Wu, J., & Hou, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1707084 · Cited by 3
“…immune cell activation and function by binding to its ligands, programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), thereby inhibiting T cell activation and function, regulating the magnitude and duration of immune responses, and maintaining immune tolerance and balance (7 – 9).”
Nam, N. H., Taura, K., Koyama, Y., Nishio, T., Yamamoto, G., Uemoto, Y., Kimura, Y., Xuefeng, L., Nakamura, D., Yoshino, K., et al. (2021) · Liver Transplantation · doi:10.1002/lt.26336 · Cited by 4
Establishment of a diagnostic model based on immune-related genes in children with asthma
Yuan, Y., Zhu, H., Huang, S., Zhang, Y., & Shen, Y. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25735 · Cited by 3
“PDCD1 gene, is a transmembrane receptor protein in CD28/CTLA-4 subfamily and is broadly expressed in various hematopoietic cells and other tissues [58].”
BackgroundLi, Y., Chen, Y., Wang, D., Wu, L., Li, T., An, N., & Yang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1442722 · Cited by 5
“Speci fi cally, these therapeutic agents enhance immune function by lifting the inhibitory effects on T-cells imposed by the PD-1 or PD-L1 proteins (42 – 44).”
BackgroundLiu, Z., Wang, G., Liu, H., Ding, K., Song, J., & Fu, R. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117133 · Cited by 5
A review of immunotherapy for bone tumors
Wang, C., Chen, Z., Mo, H., Wang, J., & Zhou, W. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1580598 · Cited by 6
“PD-L1 expression is upregulated in the presence of interferon g , possibly originating from tumor-in fi ltrating effector T cells (61, 62).”
Metadata
- Authors
- Okazaki, T., & Honjo, T.
- Affiliations
- Kyoto University (JP)
- ORCID
- Okazaki, T.
- Venue
- International Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-06-22
- Volume
- 19
- Issue
- 7
- Pages
- 813-824
- ISSN
- 0953-8178 (ISSN-L)
- 1460-2377
- OpenAlex
- W2122639773
- Cited by
- 1,310
- References
- 138
- Citations by year
- 2026: 26 · 2025: 53 · 2024: 96 · 2023: 94 · 2022: 100 · 2021: 125 · 2020: 152 · 2019: 101 · 2018: 100 · 2017: 112 · 2016: 72 · 2015: 70 · 2014: 41 · 2013: 48 · 2012: 29
- FWCI
- 1.94
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Biomedical Innovation
- Japan Society for the Promotion of Science (17047024, 19689012)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- PD-1, PD-L1, PD-L2, immune checkpoint, SHP2, autoimmunity, antitumor immunity, transplantation immunity, allergy, immune privilege, clinical application
- MeSH terms
- Animals, Autoimmune Diseases, Humans, Immunity, Ligands, Antigens, CD, Intercellular Signaling Peptides and Proteins, Mice, B7-H1 Antigen, Programmed Cell Death 1 Ligand 2 Protein
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.